Orthocell Chairman John Van Der Wielen spoke with Stockhead to discuss the Company’s strategic positioning ahead of its US market entry, sharing insights on why Remplir represents a compelling investment opportunity.
Meet The Board | Independent Director, Dr. Ravi Thadhani
The fourth episode of Orthocell’s ‘Meet the Board’ video series is now live – featuring Independent Director, Dr. Ravi Thadhani.
Appointment of Key US Executives to Lead Remplirâ„¢ Launch
Orthocell has appointed two experienced US-based executives to drive the market launch and sales of Remplirâ„¢ following the expected US FDA approval in the first quarter of 2025.
Equity Mates Podcast
Orthocell has been named as a biotech stock to watch on a recent episode the Equity Mates Investing Podcast.
The West Australian | Orthocell confirms record $17 million raising to launch in the US
Orthocell’s record $17 million capital raise has been featured in The West Australian newspaper in an article titled “Orthocell confirms record $17 million raising to launch in the US” by journalist Sean Smith.Â
$17 million placement to fund US launch of Remplirâ„¢ and drive further growth
Orthocell has today announced that it has received firm commitments for a $17 million capital raising via an institutional placement.
Meet The Board | Chairman, John Van Der Wielen
The third episode of Orthocell’s ‘Meet the Board’ video series is now online – featuring Chairman, John Van Der Wielen.
Executive Series | Meet The Board | Professor Fiona Wood AM
In the second instalment of the ‘Meet The Board’ video series, we meet Professor Fiona Wood, a world-renowned plastic and reconstructive surgeon, and valued member of the Orthocell Board.
Orthocell Receives Regulatory Approval for Remplirâ„¢ in SingaporeÂ
Orthocell has received regulatory approval from the Health Sciences Authority (HSA) in Singapore, allowing the Company to commence sales of its market leading nerve repair product, Remplirâ„¢
Orthocell Reports Second Consecutive Quarter of Record Revenue
Orthocell has today announced continued growth in sales of its market-leading medical devices, Striate+â„¢ and Remplirâ„¢.